BACKGROUND: The 'gold standard' for the diagnosis of melanocytic lesions is dermatopathology. Although most of the diagnostic criteria are clearly defined, the interpretation of histopathology slides may be subject to interobserver variability. OBJECTIVES: The aim of this study was to determine the variability among dermatopathologists in the interpretation of clinically difficult melanocytic lesions. METHODS: This study used the database of MelaFind®, a computer-vision system for the diagnosis of melanoma. All lesions were surgically removed and sent for independent evaluation by four dermatopathologists. Agreement was calculated using kappa statistics. RESULTS: A total of 1,249 pigmented melanocytic lesions were included. There was a substantial agreement among expert dermatopathologists: two-category kappa was 0.80 (melanoma vs. non-melanoma) and three-category kappa was 0.62 (malignant vs. borderline vs. benign melanocytic lesions). The agreement was significantly greater for patients ≥40 years (three-category kappa = 0.67) than for younger patients (kappa = 0.49). In addition, the agreement was significantly lower for patients with atypical mole syndrome (AMS) (kappa = 0.31) than for patients without AMS (kappa = 0.76). LIMITATIONS: The data were limited by the inclusion/exclusion criteria of the MelaFind® study. This might represent a selection bias. The agreement was evaluated using kappa statistics. This is a standard method for evaluating agreement among pathologists, but might be considered controversial by some statisticians. CONCLUSIONS: Expert dermatopathologists have a high level of agreement when diagnosing clinically difficult melanocytic lesions. However, even among expert dermatopathologists, the current 'gold standard' is not perfect. Our results indicate that lesions from younger patients and patients with AMS may be more problematic for the dermatopathologists, suggesting that improved diagnostic criteria are needed for such patients.
BACKGROUND: The 'gold standard' for the diagnosis of melanocytic lesions is dermatopathology. Although most of the diagnostic criteria are clearly defined, the interpretation of histopathology slides may be subject to interobserver variability. OBJECTIVES: The aim of this study was to determine the variability among dermatopathologists in the interpretation of clinically difficult melanocytic lesions. METHODS: This study used the database of MelaFind®, a computer-vision system for the diagnosis of melanoma. All lesions were surgically removed and sent for independent evaluation by four dermatopathologists. Agreement was calculated using kappa statistics. RESULTS: A total of 1,249 pigmented melanocytic lesions were included. There was a substantial agreement among expert dermatopathologists: two-category kappa was 0.80 (melanoma vs. non-melanoma) and three-category kappa was 0.62 (malignant vs. borderline vs. benign melanocytic lesions). The agreement was significantly greater for patients ≥40 years (three-category kappa = 0.67) than for younger patients (kappa = 0.49). In addition, the agreement was significantly lower for patients with atypical mole syndrome (AMS) (kappa = 0.31) than for patients without AMS (kappa = 0.76). LIMITATIONS: The data were limited by the inclusion/exclusion criteria of the MelaFind® study. This might represent a selection bias. The agreement was evaluated using kappa statistics. This is a standard method for evaluating agreement among pathologists, but might be considered controversial by some statisticians. CONCLUSIONS: Expert dermatopathologists have a high level of agreement when diagnosing clinically difficult melanocytic lesions. However, even among expert dermatopathologists, the current 'gold standard' is not perfect. Our results indicate that lesions from younger patients and patients with AMS may be more problematic for the dermatopathologists, suggesting that improved diagnostic criteria are needed for such patients.
Authors: Richard R Winkelmann; Darrell S Rigel; Laura Ferris; Arthur Sober; Natalie Tucker; Clay J Cockerell Journal: J Clin Aesthet Dermatol Date: 2016-03-01
Authors: Patricia A Carney; Lisa M Reisch; Michael W Piepkorn; Raymond L Barnhill; David E Elder; Stevan Knezevich; Berta M Geller; Gary Longton; Joann G Elmore Journal: J Cutan Pathol Date: 2016-07-01 Impact factor: 1.587
Authors: Michael N Kent; Thomas G Olsen; Theresa A Feeser; Katherine C Tesno; John C Moad; Michael P Conroy; Mary Jo Kendrick; Sean R Stephenson; Michael R Murchland; Ayesha U Khan; Elizabeth A Peacock; Alexa Brumfiel; Michael A Bottomley Journal: JAMA Dermatol Date: 2017-12-01 Impact factor: 10.282
Authors: Damon Reed; Ragini Kudchadkar; Jonathan S Zager; Vernon K Sondak; Jane L Messina Journal: J Natl Compr Canc Netw Date: 2013-06-01 Impact factor: 11.908
Authors: A Blum; J Kreusch; W Stolz; H Haenssle; R Braun; R Hofmann-Wellenhof; P Tschandl; I Zalaudek; H Kittler Journal: Hautarzt Date: 2017-08 Impact factor: 0.751
Authors: Patricia A Carney; Paul D Frederick; Lisa M Reisch; Linda Titus; Stevan R Knezevich; Martin A Weinstock; Michael W Piepkorn; Raymond L Barnhill; David E Elder; Donald L Weaver; Joann G Elmore Journal: J Cutan Pathol Date: 2018-04-26 Impact factor: 1.587
Authors: Rahat S Azfar; Robert A Lee; Leslie Castelo-Soccio; Martin S Greenberg; Warren B Bilker; Joel M Gelfand; Carrie L Kovarik Journal: JAMA Dermatol Date: 2014-06 Impact factor: 10.282
Authors: Mustufa A Jafry; Sue Peacock; Andrea C Radick; Hannah L Shucard; Lisa M Reisch; Michael W Piepkorn; Stevan R Knezevich; Martin A Weinstock; Raymond L Barnhill; David E Elder; Kathleen F Kerr; Joann G Elmore Journal: J Am Acad Dermatol Date: 2019-12-17 Impact factor: 11.527
Authors: Rami N Al-Rohil; Jessica L Moore; Nathan Heath Patterson; Sarah Nicholson; Nico Verbeeck; Marc Claesen; Jameelah Z Muhammad; Richard M Caprioli; Jeremy L Norris; Sara Kantrow; Margaret Compton; Jason Robbins; Ahmed K Alomari Journal: J Cutan Pathol Date: 2021-07-02 Impact factor: 1.587